TB-500

TB-500, a synthetic fragment of thymosin beta-4, is being investigated for several potential therapeutic applications, though clinical evidence remains limited.

Current Clinical Investigation

Cardiovascular Applications
A Phase I/II clinical trial (NCT07487363) is currently recruiting participants to evaluate TB-500's effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). This represents the primary area of formal clinical investigation for TB-500.

Proposed Applications Based on Research

Musculoskeletal and Sports Medicine
Recent reviews have identified TB-500 among peptide therapies being used for musculoskeletal injuries and athletic performance enhancement. However, the available literature primarily discusses TB-500 in the context of "unapproved peptide therapies," indicating limited regulatory approval for these applications.

Wound Healing
Laboratory studies have demonstrated TB-500's wound healing activities in vitro, with research establishing methods to quantify the peptide and its metabolites in experimental models. This preclinical work suggests potential applications in tissue repair, though human clinical data is lacking.

Aging and Longevity Medicine
TB-500 has been mentioned in discussions of therapeutic peptides for healthy aging applications, though specific clinical outcomes data in geriatric populations is not well-established in the current literature.

Clinical Evidence Limitations

The clinical evidence for TB-500 remains sparse. Most available research consists of:

• Analytical methods for detection and measurement
• In vitro studies of biological activity
• Reviews discussing potential applications rather than clinical outcomes
• A single ongoing clinical trial in cardiovascular disease

The peptide appears in anti-doping literature, suggesting its use in athletic contexts, but this does not constitute evidence of safety or efficacy for performance enhancement.

Disclaimer: This information is for educational purposes only and should not be considered personalized medical advice. Consult qualified healthcare providers for medical decisions regarding peptide therapies.